This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer: Allergan Is a Favorite Stock, Teva Deal Was 'Incredible'

8/01/15 9:00 AM EDT
Jim Cramer, portfolio manager of Action Alerts PLUS, and research director Jack Mohr sat down to talk about their ‘favorite company in the portfolio:’ Allergan. Allergan made headlines this week after the pharmaceutical company sold off its generics business to Israeli company Teva Pharmaceuticals in a ‘transformative’ deal that totaled $40.5 billion. Cramer knows Allergan’s CEO Brenton Saunders and says that Saunders ‘recognizes that with the coming consolidations that… they will then become much tougher on the generic industry.’ Cramer says that they will not be as tough on the proprietary drug however because ‘there’s not much you can do’ since ‘there is no other offset.’ Cramer says that at $40.5 billion Allergan got rid of its generics business, which historically has had margin problems, for seventeen times EBITDA. The deal allows Allergan to secure its balance sheet by offsetting the $40 billion in debt owned by the company. Cramer says that Allergan was also able to buy a stake in Teva in case the Teva stock were to go up, which ended up being the case. Cramer says that overall, the Teva deal was ‘a huge win for Brenton Saunders.’ Analysts are putting $400 price targets on Allergan and Cramer says that these targets ‘are very realistic’ and wants people ‘to buy Allergan.’ -- Get Cramer's top stocks with Action Alerts PLUS Trade with him FREE for 14-days.
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs